Table 6.

Ongoing trials on systemic treatment of brain metastases from HER2/HER3-positive breast cancer.

Study Name	Phase	NCT Number
HER2 targeted
HER2-CAR T Cells in Treating Patients with Recurrent Brain or Leptomeningeal Metastases	Phase I	NCT03696030
Secondary Brain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With advanced Human Epidermal Growth Factor Receptor 2+ Breast Cancer with the Addition of Tucatinib (BRIDGET)	Phase II	NCT05323955
Tucatinib, Trastuzumab and Capecitabine With SRS for Brain Metastases From HER-2-Positive Breast Cancer	Phase I	NCT05553522
Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant Treatment in Patients with Brain Metastasis From ER/PR-Positive, HER-2-Positive Breast Cancer: A Multi-center, Prospective Study in China	Phase II	NCT04334330
Pyrotinib Combined with Capecitabine and Bevacizumab for Patients with HER2-Positive Breast Cancer and Brain Metastases	Phase II	NCT06152822
A Study of Pyrotinib Plus Capecitabine Combined with SRT in HER2+ MBC With Brain Metastases	Phase II	NCT05042791
Trial of Neratinib Plus Capecitabine in Subjects with HER2-Negative Metastatic Breast Cancer with Brain Metastases and Abnormally Active HER2 Signaling	Phase II	NCT04965064
GDC-0084 in Combination with Trastuzumab for Patients with HER2-Positive Breast Cancer Brain Metastases	Phase II	NCT03765983
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain Metastases	Phase II	NCT05769010
A Study of Tucatinib Given Before Surgery to People with HER2+ Cancers That Have Spread to the Brain	Phase II	NCT05892068
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis from Triple-Negative Breast Cancer or HER2+ Breast Cancer	Phase II	NCT04348747
HER3 targeted
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3)	Phase II	NCT05865990